Endocrine treatment for ductal carcinoma in situ: Balancing risks and benefits

The Lancet

Volumn 387, Issue 10021, 2016, Pages 819-821

  Johnston, Stephen R D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; HORMONE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED CLINICAL TRIAL (TOPIC); EXCISION; HUMAN; INTRADUCTAL CARCINOMA; META ANALYSIS (TOPIC); NOTE; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; PREVENTION AND CONTROL; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 84959477466     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01219-2     Document Type: Note

References (13)

1. KJ Van Zee, J White, M Morrow, J Harris Ductal carcinoma in situ and microinvasive breast cancer JR Harris ME Lippman M Morrow CK Osborne Diseases of the breast 5th edn. 2014 Wolters Kluwer Health Philadelphia 337 356
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
3. B Fisher, N Dignam, N Wolmark et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 1999 1993 2000
4. J Houghton, WD George, J Cuzick et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial Lancet 362 2003 95 102
5. J Cuzick, I Sestak, SE Pinder et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial Lancet Oncol 12 2011 21 29
6. DC Allred, SJ Anderson, S Paik et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor positive ductal carcinoma in situ, a study based on NSABP protocol B-24 J Clin Oncol 30 2012 1268 1273
7. J Cuzick, I Sestak, M Baum on behalf of the ATAC/LATTE investigators Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 2010 1135 1141
8. Arimidex Tamoxifen Alone or in Combination Trialists' Group A Buzdar, A Howell et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 2006 633 643
9. RG Margolese, RS Cecchini, TB Julian et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial Lancet 2015 published online Dec 10. http://dx.doi.org/10.1016/S0140-6736(15)01168-X
10. JF Forbes, I Sestak, A Howell on behalf of the IBIS-II investigators Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial Lancet 2015 published online Dec 11. http://dx.doi.org/10.1016/S0140-6736(15)01129-0
11. PA Ganz, RS Cecchini, TB Julian et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial Lancet 2015 published Dec 10. http://dx.doi.org/10.1016/S0140-6736(15)01169-1
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 386 2015 1341 1352
13. S Nofech-Mozes, J Spayne, E Rakovitch et al. Prognostic and predictive molecular markers in DCIS: a review Adv Anat Pathol 12 2005 256 264